Wire · opportunities
PEDMARK Hearing Protection Shows No Cancer Efficacy Compromise in Study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The Phase 2 STS-J01 study in Japan demonstrates PEDMARK's hearing protection does not reduce cisplatin's cancer-killing efficacy in pediatric solid tumor patients, supporting broader clinical confidence. This local investigator-led data adds regulatory credibility and may accelerate Japanese market access beyond existing FDA approval.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Oncologists waiting on safer cisplatin use will see new prescribing confidence in Japan as local data reduces doubts about hearing protection interfering with cancer treatment. You should prepare for new local access paths and consider market entry opportunities linked to this regulator-backed study.
◆ Coverage
1 source · 18 Sep 2026
◆ Related on Wire
◆ Topics